EL7.AI
StocksMediumUpdated•Originally published 30 September 2026•Updated 1 October 2026•
1 min read

Wave Life Sciences Triggers $12M Milestone Payment from GSK for siRNA Program

Key Facts

1GSK selected an siRNA program for a hepatology indication from Wave Life Sciences to transition into its development pipeline.
2The selection triggers a $12 million milestone payment to Wave Life Sciences.
3Wave is eligible for additional milestones of $330-$375 million plus tiered royalties for each collaboration program.

Wave Life Sciences announced that GSK has selected an siRNA program for a hepatology indication to transition into its development pipeline. Investing News Network reported that the selection triggers a $12 million milestone payment to Wave Life Sciences. The transition is part of an ongoing collaboration where GSK leverages Wave's proprietary SpiNA design technology for drug development.

WVE closed at $3.64 on September 29, 2026, having reached a day high of $3.78 and a low of $3.56. Under the agreement terms, Wave remains eligible for additional milestone payments ranging from $330 million to $375 million, plus tiered royalties for each collaboration program.

Latest Updates · 1

  1. Major·

    Update: Wave Life Sciences announced on October 1, 2026, that FDA feedback supports a registrational pathway for WVE-006. The company plans to conduct a single two-year registrational trial, which will include a one-year interim analysis to support a potential accelerated approval pathway.